Press Releases

Press Releases

Samsung Biologics Wins 2018 CMO Leadership Awards in All Six Core Categories Two Years in a Row


CMO Leadership Awards

[NY, USA] March 21, 2018 ? Samsung Biologics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, is pleased to announce that it has won all six core categories two years in a row in the 7th annual CMO Leadership Awards presented by Life Science Leader.


 


The company has received CMO Leadership Awards including this year’s awards for the fifth consecutive year since 2013, proving Samsung’s highest quality of biologics manufacturing service to global customers 


 


The awards are in recognition of the highest level of accomplishment that drug development and manufacturing organizations have attained in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “They are especially meaningful because recipients are only evaluated by the customers they have actually worked with, and include the six critical categories of capabilities, compatibility, expertise, quality, reliability and service. An award in any of these categories adds to the distinction and reputation of CMOs throughout the global drug discovery, development, manufacturing and marketing industries.”


 


For the 2018 CMO Leadership Awards, more than 110 CMOs around the world were evaluated on 23 performance metrics to determine winners in the six categories. 


 


Industry Standard Research is honored to conduct the market research for Life Science Leader’s CMO Awards. ISR’s stringent screening processes and the high caliber of qualification required to participate in our contract manufacturing benchmarking market research means that real customers provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR’s market research to make confident business decisions based on the experiences of their industry peers.” Andrew Schafer, President of Industry Standard Research. 


 


"Samsung Biologics is honored to once again receive the CMO Leadership Award, which recognizes the reputable partner for global customer’s manufacturing needs. Being recognized in all core criteria ? capabilities, compatibility, expertise, quality, reliability and service ? attests to our solid position as a one stop service provider for mammalian biopharmaceutical products through our flexible and state of-the-art facilities,” said TH Kim, CEO of Samsung BioLogic. “We'll continue to provide quality-driven CGMP manufacturing for flexible and cost-effective services that exceed our customers’ expectations.”


 


Samsung Biologics, being responsible from clinical development to commercial manufacturing, aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency and ensures highest quality products for the patient.


 


Samsung Biologics’ Plant 3 facility was mechanically completed last November. It has 180,000 liters capacity and is expected to be CGMP operational by Q4 2018. 


 


 

-E N D ?


 

 


CMO Leadership Awards 

[NY, USA] March 21, 2018 – Samsung Biologics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, is pleased to announce that it has won all six core categories two years in a row in the 7th annual CMO Leadership Awards presented by Life Science Leader.


 


The company has received CMO Leadership Awards including this year’s awards for the fifth consecutive year since 2013, proving Samsung’s highest quality of biologics manufacturing service to global customers


 


The awards are in recognition of the highest level of accomplishment that drug development and manufacturing organizations have attained in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “They are especially meaningful because recipients are only evaluated by the customers they have actually worked with, and include the six critical categories of capabilities, compatibility, expertise, quality, reliability and service. An award in any of these categories adds to the distinction and reputation of CMOs throughout the global drug discovery, development, manufacturing and marketing industries.”


 


For the 2018 CMO Leadership Awards, more than 110 CMOs around the world were evaluated on 23 performance metrics to determine winners in the six categories.


 


Industry Standard Research is honored to conduct the market research for Life Science Leader’s CMO Awards. ISR’s stringent screening processes and the high caliber of qualification required to participate in our contract manufacturing benchmarking market research means that real customers provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR’s market research to make confident business decisions based on the experiences of their industry peers.” Andrew Schafer, President of Industry Standard Research.


 


"Samsung Biologics is honored to once again receive the CMO Leadership Award, which recognizes the reputable partner for global customer’s manufacturing needs. Being recognized in all core criteria – capabilities, compatibility, expertise, quality, reliability and service – attests to our solid position as a one stop service provider for mammalian biopharmaceutical products through our flexible and state of-the-art facilities,” said TH Kim, CEO of Samsung BioLogic. “We'll continue to provide quality-driven CGMP manufacturing for flexible and cost-effective services that exceed our customers’ expectations.”


 


Samsung Biologics, being responsible from clinical development to commercial manufacturing, aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency and ensures highest quality products for the patient.


 


Samsung Biologics’ Plant 3 facility was mechanically completed last November. It has 180,000 liters capacity and is expected to be CGMP operational by Q4 2018.


 


 

-E N D –


 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION